...
首页> 外文期刊>Thrombosis and Haemostasis: Journal of the International Society on Thrombosis and Haemostasis >High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.
【24h】

High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin.

机译:患有遗传性S蛋白,C蛋白或抗凝血酶缺乏症的患者,长期复发性静脉血栓栓塞的绝对风险较高。

获取原文
获取原文并翻译 | 示例

摘要

Hereditary deficiencies of protein S, protein C and antithrombin are known risk factors for first venous thromboembolism. We assessed the absolute risk of recurrence, and the contribution of concomitant thrombophilic defects in a large cohort of families with these deficiencies. Annual incidence of recurrence was estimated in 130 deficient patients, with separate estimates for those with each of protein S, protein C, and antithrombin deficiency, and in eight non-deficient patients with prior venous thromboembolism. All patients were also tested for factor V Leiden, prothrombin G20210A, high levels of factors VIII, IX and XI, and hyperhomocysteinemia. There were 81 recurrent events among 130 deficient patients. Median follow-up was 4.6 years. Annual incidences (95% confidence interval) of recurrent venous thromboembolism were 8.4% (5.8-11.7) for protein S deficiency, 6.0% (3.9-8.7) for protein C deficiency, 10.0% (6.1-15.4) for antithrombin deficiency, and overall 7.7% (6.1-9.5). Relative risk of recurrence in patients with a spontaneous versus provoked first event was 1.5 (0.95-2.3). Cumulative recurrence rates at 1, 5 and 10 years were 15%, 38% and 53%. Relative risk of recurrence with concomitant defects was 1.4 (0.7-2.6) (1 defect) and 1.4 (0.8-2.7) (> or =2 defects). Annual incidence was 1.0% (0.03-5.5) in eight non-deficient patients. Annual incidence of major bleeding in deficient patients on oral anticoagulant treatment was 0.5% (0.2-1.0). We conclude that patients with a hereditary protein S, protein C or antithrombin deficiency appear to have a high absolute risk of recurrence. This risk is increased after a first spontaneous event, and by concomitance of other thrombophilic defects.
机译:蛋白质S,蛋白质C和抗凝血酶的遗传缺陷是第一静脉血栓栓塞的已知危险因素。我们评估了绝对复发的风险,以及大量患有这些缺陷的家庭的伴随血栓形成缺陷的影响。估计130例患者的年复发率,其中分别患有蛋白S,蛋白C和抗凝血酶缺乏症的患者以及8例既往有静脉血栓栓塞的非缺陷患者,分别进行了估计。还对所有患者进行了V因子莱顿,凝血酶原G20210A,高水平的VIII,IX和XI因子和高同型半胱氨酸血症的检测。 130名缺陷患者中有81次复发事件。中位随访时间为4.6年。复发性静脉血栓栓塞的年发生率(95%置信区间)为S蛋白缺乏症的8.4%(5.8-11.7),C蛋白缺乏症的6.0%(3.9-8.7),抗凝血酶缺乏症的10.0%(6.1-15.4)和总体7.7%(6.1-9.5)。自发性和诱发性首发患者的相对复发风险为1.5(0.95-2.3)。在1、5和10年时的累积复发率分别为15%,38%和53%。伴随缺陷复发的相对风险为1.4(0.7-2.6)(1个缺陷)和1.4(0.8-2.7)(>或= 2缺陷)。 8名非缺陷患者的年发病率为1.0%(0.03-5.5)。口服抗凝药物治疗不足的患者的年大出血年发生率为0.5%(0.2-1.0)。我们得出结论,患有遗传性蛋白S,蛋白C或抗凝血酶缺乏症的患者似乎具有很高的绝对复发风险。在第一次自发事件之后,以及其他血栓亲和性缺陷的伴随,这种风险会增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号